Stay updated on Nivolumab/Daratumumab in Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab/Daratumumab in Multiple Myeloma Clinical Trial page.

Latest updates to the Nivolumab/Daratumumab in Multiple Myeloma Clinical Trial page
- Check3 days agoChange DetectedThe study page now shows a new revision label (v3.6.4), indicating a version update. The rest of the content, including trial details and eligibility information, appears unchanged.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedRevision label updated from v3.6.2 to v3.6.3 on the page, representing a small metadata update to the page.SummaryDifference0.0%

- Check31 days agoChange DetectedThe study page was updated from revision v3.6.0 to v3.6.2, signaling a maintenance update to the page. It does not alter the study details, eligibility criteria, or results.SummaryDifference0.0%

- Check45 days agoChange DetectedThe page now shows that recruitment is closed, indicating no new participants will be enrolled. This clarifies the study's current status for participants and investigators reviewing eligibility and enrollment options.SummaryDifference0.3%

- Check53 days agoChange DetectedThe page's revision tag was updated from v3.5.4 to v3.5.5, signaling a minor site update.SummaryDifference0.0%

- Check74 days agoChange DetectedThe page now displays Revision: v3.5.4, replacing the previous v3.5.3, indicating a new site/template revision has been applied. This appears to be a minor metadata update rather than a change to study content.SummaryDifference0.0%

Stay in the know with updates to Nivolumab/Daratumumab in Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab/Daratumumab in Multiple Myeloma Clinical Trial page.